Matt Davidson is the co-founder and former CEO of Verrica Pharmaceuticals.
Davidson founded Verrica in 2013—a year after he received his Ph.D—and led the company as CEO and chairman as they developed dermatology therapeutics for skin diseases that required medical interventions. Their core technologies resulted in six patents.
He helped guide Verrica from the preclinical stage to its IPO in 2018, raising $75 million to push several projects to clinical development. In his time with the company, Davidson raised over $100 million from various angel, seed, and series A and B financing. He turned the CEO reins over to Novartis veteran, Ted White, in 2018, and he formally stepped away from Verrica in 2020 to pursue other opportunities.
Davidson went on to found biotechnology company, MGD Ventures, in 2018 and pharmaceutical company, Azora Therapeutics, in 2019. MGD Ventures invests in and advises life science companies with clinically derisked assets for unmet clinical needs. Companies they have advised include VioSera Therapeutics (resistance suppression), August Therapeutics (eating disorders and obesity) and Palmm (hyperhidrosis).
He was also a scientist at Applied Immunology (acquired by Precision for Medicine) in 2013 and a research technician at the Howard Hughes Medical Institute from 2006 to 2007.
Previously, Davidson founded, developed and commercialized Think Gum, a “brain-boosting” chewing gum that enhances memory. Think Gum was the winner of the first Stanford University Student Enterprises Ventures competition (now Start-X) in 2007, and it was acquired by Think Products in 2019.
Davidson holds a Ph.D in immunology from the Stanford University School of Medicine and a B.A. in molecular and cellular biology from the University of California, Berkeley. He is also a graduate of Stanford University Graduate School of Business’ Ignite Program.
What is Matt Davidson's net worth?
The estimated net worth of Matt Davidson is at least $2.25 million as of August 29th, 2019. Mr. Davidson owns 2,577,681 shares of Verrica Pharmaceuticals stock worth more than $2,252,378 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Davidson may own. Learn More about Matt Davidson's net worth.
How do I contact Matt Davidson?
Has Matt Davidson been buying or selling shares of Verrica Pharmaceuticals?
Matt Davidson has not been actively trading shares of Verrica Pharmaceuticals during the past quarter. Most recently, Matt Davidson sold 19,314 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $10.89, for a transaction totalling $210,329.46. Learn More on Matt Davidson's trading history.
Who are Verrica Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Verrica Pharmaceuticals?
During the last year, Verrica Pharmaceuticals insiders bought shares 5 times. They purchased a total of 1,337,691 shares worth more than $7,938,546.19. During the last year, insiders at the sold shares 2 times. They sold a total of 57,930 shares worth more than $408,985.80. The most recent insider tranaction occured on July, 22nd when CEO Ted White sold 32,469 shares worth more than $229,231.14. Insiders at Verrica Pharmaceuticals own 42.6% of the company.
Learn More about insider trades at Verrica Pharmaceuticals. Information on this page was last updated on 7/22/2024.
